Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
Key Points Shares of Gilead Sciences (NASDAQ: GILD) have lagged the S&P 500 average this year, rising only 9% despite…
Key Points Shares of Gilead Sciences (NASDAQ: GILD) have lagged the S&P 500 average this year, rising only 9% despite…
Key Points When choosing dividend stocks or ETFs, it’s important to look beyond just the yield figure. Ultimately, total returns…
Key Points If you’re counting on Social Security to cover a large share of your retirement expenses, the thought of…
Key Points Google could lower its AI compute costs by up to 30% using its own processors. The company is…
Key Points In the stock market, many things are true, and new investors can and do learn at least two…
Key Points Amazon is the largest cloud computing company, and AWS revenue has started to accelerate. Microsoft has been seeing…
Macro shifts, rate moves, and the patterns most investors miss — delivered every week before the market opens.
Trusted by portfolio managers, analysts, and independent investors. No spam. Unsubscribe anytime.
Eagle One Intelligence
Macro shifts, market structure, and the ideas worth tracking — straight to your inbox before the crowd figures it out.